Evidence map›Paper›PMID 35819517›Full record

ArticleVirchows Archiv : an international journal of pathology2022

EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.

R J Leguit, A Orazi, N Kucine, H M Kvasnicka, U Gianelli, D A Arber, A Porwit, M Ponzoni

Open access · hybridAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 5 countries.

R J LeguitDepartment of Pathology, University Medical Center Utrecht, H04-312, POB 85500, 3508, GA, Utrecht, The Netherlands. R.J.Leguit-2@umcutrecht.nl.ORCID http://orcid.org/0000-0001-9990-2802
A OraziDepartment of Pathology, Texas Tech University Health Sciences Center El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA.ORCID http://orcid.org/0000-0002-1660-7013
N KucineDepartment of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, 525 E. 68th St, Payson-695, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-4865-4033
H M KvasnickaInstitute of Pathology and Molecular Pathology, University of Witten/Herdecke, Witten, Germany.ORCID http://orcid.org/0000-0002-5450-4840
U GianelliPathology Unit, Department of Pathophysiology and Transplantation, University of Milan and IRCCS Fondazione Ca' Granda - Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy.ORCID http://orcid.org/0000-0003-3304-8417
D A ArberDepartment of Pathology, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2160-9689
A PorwitFaculty of Medicine, Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-0709-2713
M PonzoniVita Salute San Raffaele University and Pathology and Lymphoid Malignancies Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cornell University · USLund University · SETexas Tech University · USUniversity of Chicago · USUniversity of Milan · ITUtrecht University · NLVita-Salute San Raffaele University · ITWitten/Herdecke University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first section of the bone marrow workshop of the European Association of Haematopathology (EAHP) 2020 Virtual Meeting was dedicated to pediatric myeloid neoplasms. The section covered the whole spectrum of myeloid neoplasms, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and acute myeloid leukemia (AML). The workshop cases are hereby presented, preceded by an introduction on these overall rare diseases in this age group. Very rare entities such as primary myelofibrosis, pediatric MDS with fibrosis, and MDS/MPN with JMML-like features and t(4;17)(q12;q21); FIP1L1::RARA fusion, are described in more detail.

Indexed as

Myelodysplastic-Myeloproliferative DiseasesMyelodysplastic SyndromesMyeloproliferative DisordersNeoplasmsBone MarrowChildHumansAcute leukemiaBone marrow biopsyEAHP workshopJuvenile myelomonocytic leukemiaMyelodysplastic syndromeMyeloproliferative neoplasmPediatric

Identifiers

PMID35819517
PMCPMC9534825
OpenAlexW4285077808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.